Astellas and Seagen Complete Enrollment in EV-103 Trial Coho

/PRNewswire/ -- Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and Seagen Inc. (Nasdaq:SGEN) today announced that...

Related Keywords

Kenilworth , District Of Columbia , United States , Tokyo , Japan , California , Washington , Canada , Switzerland , Seattle , American , Kenji Yasukawa , Roger Dansey , Andrew Krivoshik , American Society Of Clinical Oncology , Twitter , Astellas Pharma Us Inc , Nasdaq , Merck Co Inc , Astellas Pharma Inc , International Agency For Research On Cancer , European Union , Head Of Development Therapeutic Areas , American Cancer Society , Drug Administration , Merck Sharp Dohme Corp , Seagen Inc , Exchange Commission , Most Common Adverse Reactions Including Laboratory Abnormalities , Prnewswire Astellas Pharma Inc , Chief Medical Officer , Breakthrough Therapy , Senior Vice President , Development Therapeutic Areas , Toxic Epidermal Necrolysis , Safety Information , Common Adverse Reactions , Including Laboratory Abnormalities , Dualp Gp , Prescribing Information , Focus Area Approach , Merck Sharp , Dohme Corp , Quarterly Report , Cancer Facts , Accessed October , Cancer Tomorrow , Vedotin Antibody Drug Conjugate Targeting , Highly Potent Therapeutic Agent , Multiple Preclinical Cancer , Cancer Res , Astellas Pharma ,